J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.

Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.

Fate has announced the retirement of president and CEO Scott Wolchko with Bob Valamehr set to assume the role from 1 January ...

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.